QR-313, an Antisense Oligonucleotide, Shows Therapeutic Efficacy for Treatment of Dominant and Recessive Dystrophic Epidermolysis Bullosa: A Preclinical Study
Open Access
- 15 September 2020
- journal article
- research article
- Published by Elsevier BV in Journal of Investigative Dermatology
- Vol. 141 (4), 883-893.e6
- https://doi.org/10.1016/j.jid.2020.08.018
Abstract
No abstract availableKeywords
Funding Information
- Deutsche Forschungsgemeinschaft
This publication has 36 references indexed in Scilit:
- Collagen VII plays a dual role in wound healingJCI Insight, 2013
- Inherited epidermolysis bullosaOrphanet Journal of Rare Diseases, 2010
- Dominant-negative Effects of COL7A1 Mutations Can be Rescued by Controlled Overexpression of Normal Collagen VIIOnline Journal of Public Health Informatics, 2009
- Mechanisms of Fibroblast Cell Therapy for Dystrophic Epidermolysis Bullosa: High Stability of Collagen VII Favors Long-term Skin IntegrityMolecular Therapy, 2009
- Characterization of Molecular Mechanisms Underlying Mutations in Dystrophic Epidermolysis Bullosa Using Site-directed MutagenesisOnline Journal of Public Health Informatics, 2008
- A hypomorphic mouse model of dystrophic epidermolysis bullosa reveals mechanisms of disease and response to fibroblast therapyJCI Insight, 2008
- Epidermolysis bullosa. II. Type VII collagen mutations and phenotype-genotype correlations in the dystrophic subtypesJournal of Medical Genetics, 2006
- Clustering of COL7A1 Mutations in Exon 73: Implications for Mutation Analysis in Dystrophic Epidermolysis BullosaJournal of Investigative Dermatology, 1999
- Current Concepts in Pediatric Burn Care: The Biology of Cultured Epithelial Autografts: An Eight-Year Study in Pediatric Burn Patients*European Journal of Pediatric Surgery, 1992
- Type VII collagen forms an extended network of anchoring fibrils.The Journal of cell biology, 1987